Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
Oncimmune say ImmunoINSIGHTS is driving momentum into second quarter of 2021 🏋️♀️
via @YouTube
#ONC
Fantastic & importantly very insightful comments from CEO Adam Hill, wrt the @Oncimmune's exciting runway ahead.
Vox Markets - Market Investor News, Insights & Analysis
Real time Market investment news, RNS feeds, watchlists & expert insight from Fund Managers, CEO’s & Analysts. Vox Markets the definitive source...
www.voxmarkets.co.uk
*Q&A* @OncimmuneECDT CEO, Dr Adam M Hill, discusses how the highly profitable ImmunoINSIGHTS business, the Company's autoantibody profiling service, is used by their big pharma clients and their fixed pricing model.
#investing #voxmarkets via @VOXmarkets
Oncimmune discuss their highly profitable ImmunoINSIGHTS business - Vox Markets
Oncimmune CEO, Dr Adam M Hill, discusses how the highly profitable ImmunoINSIGHTS business, the Company's autoantibody profiling service, is used by ...
www.voxmarkets.co.uk
Couldn't make yesterday's live presentation with ONCIMMUNE HOLDINGS PLC? #ONC @OncimmuneECDT
No problem! Catch up here:
Meet @NIHRresearch @KarmaOncology @LocustWalkPtrs @LSXLeaders @MicrobioticaLtd @Mogrify_UK @OncimmuneECDT @Oppilotech at the UK virutal pavillion #BIOEurope
Join them here: https://www.biopartner.co.uk/bio-europe-digital-2021
"We are delighted that this global pharmaceutical company has again chosen to partner with Oncimmune, for our world class #autoantibody #biomarker profiling technology and #autoimmune expertise." Adam M Hill @Tech_Trender
Proactive on Twitter
“$ONC Oncimmune signs agreement with big pharma group for autoimmune diseases profiling https://t.co/2mANoUohhl @OncimmuneECDT $OCY #ONC #OCY #K...
twitter.com
$ONC Oncimmune hails three-year follow-up data from landmark early detection lung cancer trial @OncimmuneECDT $OCY #ONC #OCY #Katie_Proactive
Oncimmune hails three-year follow-up data from landmark early detection lung cancer trial
Readers of the peer-reviewed article were told late-stage cancers and deaths were lower in the group of patients assessed using the company’s di...
tinyurl.com
“Investors cheered Oncimmune after the cancer specialist’s technology was used in a breakthrough Covid study… The findings looked at how Covid stimulates the immune system and predicts how people respond to vaccines and therapies against the virus.”
MARKET REPORT: IG and AJ Bell cash in on the retail trading boom
IG posted record profits of £450m in the 12 months to May - a 52 per cent rise from the year before. The number of active clients on its books rose b...
www.thisismoney.co.uk
Gallery
